NASDAQ:DMAC

Diamedica Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy DMAC

*Your capital is at risk

$5.65

-0.120 (-2.08%)

At Close: Jun 03, 2026

DiaMedica Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 22.08M and sold 0 DMAC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	22.08M shares
● Sell	0 shares
100% Buy Activity Weak Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Semba Charles Pauling Director	Director	5 290 Value: $28.2K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Semba Charles Pauling Director	Director	5 290 Value: $28.2K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Pilnik Richard D. Director	Director	10 393 Value: $55.5K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Kuntz Richard Director	Director	9 925 Value: $53.0K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Giuffre Randall Michael Director	Director	10 861 Value: $58.0K
Jan 02, 2025 Buy	Stock Option (right to buy) A-Award	Parsons James T. Director	Director	4 287 Value: $23.6K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Parsons James T. Director	Director	15 917 Value: $85.0K
Jun 28, 2024 Buy	Common Shares P-Purchase	Von Koch Thomas 10 Percent Owner	10% Owner	1 200 000 Value: $3.00M
Jun 28, 2024 Buy	Common Shares P-Purchase	Stahlberg Jan 10 Percent Owner	10% Owner	1 200 000 Value: $3.00M
Jun 28, 2024 Buy	Common Shares P-Purchase	Stahlberg Jan 10 Percent Owner	10% Owner	1 200 000 Value: $3.00M
Jun 28, 2024 Buy	Common Shares P-Purchase	Von Koch Thomas 10 Percent Owner	10% Owner	1 200 000 Value: $3.00M
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Wambeke David J. Chief Business Officer	Officer	130 000 Value: $377.0K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Kellen Scott CFO And Secretary	C-Suite Officer	130 000 Value: $377.0K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Cundari Dominic R Chief Commercial Officer	Officer	15 000 Value: $43.5K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Pauls Dietrich John President And CEO	CEO / President	300 000 Value: $870.0K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Semba Charles Pauling Director	Director	28 472 Value: $82.6K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Pilnik Richard D. Director	Director	36 065 Value: $104.6K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Parsons James T. Director	Director	28 472 Value: $82.6K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Lewis Tanya Director	Director	28 472 Value: $82.6K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Parsons James T. Director	Director	28 472 Value: $82.6K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Pilnik Richard D. Director	Director	36 065 Value: $104.6K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Semba Charles Pauling Director	Director	28 472 Value: $82.6K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Pauls Dietrich John President And CEO	CEO / President	300 000 Value: $870.0K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Cundari Dominic R Chief Commercial Officer	Officer	15 000 Value: $43.5K
Jun 01, 2024 Buy	Stock Option (right to buy) A-Award	Kellen Scott CFO And Secretary	C-Suite Officer	130 000 Value: $377.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DIAMEDICA THERAPEUTICS INC.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic ...

Read Full Profile Here